Merck & Company Inc (MRK)vsBeiGene, Ltd. (ONC)
MRK
Merck & Company Inc
$122.41
-0.98%
HEALTHCARE · Cap: $280.20B
ONC
BeiGene, Ltd.
$310.25
+0.20%
HEALTHCARE · Cap: $32.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1046% more annual revenue ($65.77B vs $5.74B). MRK leads profitability with a 13.6% profit margin vs 8.9%. MRK trades at a lower P/E of 32.0x. ONC earns a higher WallStSmart Score of 54/100 (C-).
MRK
Hold50
out of 100
Grade: D+
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.8%
Fair Value
$80.79
Current Price
$122.41
$41.62 premium
Margin of Safety
+82.2%
Fair Value
$1977.09
Current Price
$310.25
$1666.84 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 35.5% year-over-year
Earnings expanding 16971.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 70.3x leaves little room for execution misses.
Key Dynamics to Monitor
MRK profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.50 — expect wider price swings.
ONC is growing revenue faster at 35.5% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
ONC scores higher overall (54/100 vs 50/100) and 35.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?